Biotech Values

[DewDiligence]

FCSC closed the week at 0.95, down 25% since obtaining FDA approval for laViv. Evidently, I’m not the only one who recognizes that this drug will be a commercial bust.

Meanwhile, some FCSC cheerleaders on iHub maintain that laViv is guaranteed to be a hit because it’s “all natural” — even though the product requires having your cells extracted and processed in a lab for re-injection. The sad thing for FCSC longs is that the lame “all natural” shtick is probably the best argument they have.